Mike leads Life Sciences investments.
Mike has many areas of expertise but has recently focused a lot of time on the treatment of stroke and on catheter-related technologies, particularly those that reduce the incidence of nosocomial infection. Among Mike's investments are Juventas Therapeutics, Cardiox, Histosonics, Great Lakes Pharmaceuticals, and CytoPherx.
Prior to joining Early Stage Partners as Managing Director in 2008, Mike held roles in sales management and corporate acquisitions for C.R. Bard Access Systems (NYSE: BCR). As Director of Corporate Development, he created the process to evaluate medical technology investments for Bard's six centralized divisions and successfully executed 14 acquisitions, licenses, and divestitures. Later, Mike managed a field sales force and negotiated multiple contracts with hospitals.
Mike joined Medtronic (NYSE: MDT) in 1998 where he initially led a $750 million global product launch in cardiac rhythm management and served on product development, strategy and clinical committees. Mike then served in Medtronic's corporate development group, closing over ten minority investments and acquisitions in support of corporate strategy initiatives across the neurostimulation, cardiac rhythm management, orthopedic and vascular business units.
Mike also served in sales and marketing management roles earlier in his career for Apogee Enterprises and Rand McNally.
Mike is a graduate of Miami University (B.S.) where he studied Marketing, and the Kellogg Graduate School of Management at Northwestern University (M.B.A.).
Find Out More About ESP
Area of focus: Healthcare technologies
Boards: Cardiox, Histosonics, Great Lakes Pharmaceuticals, GenSyn, CytoPherx (Observer), Juventas (Observer)
Interesting facts: Plays ice hockey; avid outdoorsman